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Abstract
Background: Data on the performance of Mycobacterium-tuberculosis-specific interferon-(IFN)-g release assays
(IGRAs) in the serial testing of health care workers (HCWs) is limited. The objective of the present study was to
determine the frequency of IGRA conversions and reversions and to identify predictors of persistent IGRA positivity
among serially tested German HCWs in the absence of recent extensive tuberculosis (TB) exposure.
Methods: In this observational cohort-study HCWs were prospectively recruited within occupational safety and
health measures and underwent a tuberculin skin test (TST) and the IGRA QuantiFERON®-TB Gold In-Tube (QFT-GIT)
at baseline. The QFT-GIT was repeated 18 weeks later in the median. QFT-GIT conversions (and reversions) were
defined as baseline IFN-g < 0.35 IU/ml and follow-up IFN-g ≥ 0.35 IU/ml (and vice versa). Predictors of persistently
positive QFT-GIT results were calculated by logistic regression analysis.
Results: In total, 18 (9.9%) and 15 (8.2%) of 182 analyzed HCWs were QFT-GIT-positive at baseline and at follow-up,
respectively. We observed a strong overall agreement between baseline and follow-up QFT-GIT results ( = 0.70).
Reversions (6/18, 33.3%) occurred more frequently than conversions (3/162, 1.9%). Age and positive prior and
recent TST results independently predicted persistent QFT-GIT positivity. Furthermore, the chance of having
persistently positive QFT-GIT results raised about 3% with each additional 0.1 IU/ml increase in the baseline IFN-g
response (adjusted odds ratio 1.03, 95% confidence interval 1.01-1.04). No active TB cases were detected within an
observational period of more than two years.
Conclusions: The QFT-GIT’s utility for the application in serial testing was limited by a substantial proportion of
reversions. This shortcoming could be overcome by the implementation of a borderline zone for the interpretation
of QFT-GIT results. However, further studies are needed to clearly define the within-subject variability of the QFT-
GIT and to confirm that increasing age, concordantly positive TST results, and the extend of baseline IFN-g
responses may predict the persistence of QFT-GIT positivity over time in serially tested HCWs with only a low or
medium TB screening risk in a TB low-incidence setting.
Background
In high-income countries with a low burden of tubercu-
losis (TB) targeted screening of at-risk groups, identifica-
tion and preventive treatment of latent TB infection
(LTBI, i. e. lasting Mycobacterium-tuberculosis-[MTB]-
specific T-cell responses in the absence of clinical evi-
dence for TB disease) in individuals with recent exposure
are fundamental components of TB control strategies
[1,2]. Health care workers (HCWs) are considered at risk
for the occupational transmission of TB infection due to
nosocomial exposure [3,4]. Hence, screening procedures
within occupational safety and health (OSH) measures,
i. e. contact investigations after exposure to TB source
cases as well as the serial testing of HCWs with continu-
ous risk for workplace exposure, are required for TB sur-
veillance and with regard to the recognition and
compensation of TB as an occupational disease.
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serial testing is limited by cross-reactivity following Bacil-
lus Calmette-Guérin (BCG) vaccination and exposure to
non-tuberculous mycobacteria, nonspecific variations, and
boosting [5]. In this respect, novel interferon-(IFN)-g
release assays (IGRAs) provide distinct advantages. They
are highly MTB-specific and thus not confounded in
populations containing a high proportion of BCG-vacci-
nated individuals. They avoid boosting of immune
responses by ex-vivo testing and possess logistical conve-
niences [6,7]. Although broadly recommended and
increasingly used [8,9], data on the interpretation of IGRA
results in serial testing is scarce. A limited number of stu-
dies are available regarding the performance of IGRAs in
serial testing in high-burden countries [10-12], the effect
of treatment of active TB or LTBI on IGRA responses
[13-17], and the within-subject variability (reproducibility)
over different periods of time [18-20]. Only few studies
cover their use in HCWs in intermediate and high burden
countries [7,21,22] or general populations in high-income,
low-incidence countries [13,23-25].
Until now, no published study evaluated the perfor-
mance of an IGRA in the serial testing of HCWs in a
TB low-incidence country like Germany, where the
annual TB incidence rate was 6.1 per 100,000 popula-
tion in 2007 [26]. We hypothesized that the risk of pro-
gression to active TB among German HCWs with
persistently positive IGRA results, but without recent
extensive exposure is low, and that the repeated IGRA
testing within OSH screening measures may not have
an additive value among those subjects. In this context,
the identification of predictors of persistent IGRA posi-
tivity could contribute to the restriction of IGRA serial
testing and thus to the reduction of costs.
It was the aim of the present study to evaluate the
performance of the IGRA QuantiFERON®-TB Gold In-
Tube (QFT-GIT) in the serial testing of German HCWs
in the absence of recent extensive exposure, to deter-
mine the frequency of inconsistent QFT-GIT results
(conversions and reversions), and to identify indepen-
dent predictors of persistent QFT-GIT positivity.
Methods
Study design and subjects
In this prospective, observational cohort-study we
enrolled eligible HCWs between December 2005 and
January 2008 at three German hospitals (Bochum,
Großhansdorf, Hamburg). All HCWs were subject to
screening procedures according to German OSH legisla-
tion and were classified to low or medium TB screening
risk according to the Centers for Disease Control and
Prevention (CDC) guidelines [27].
The majority of enrolled HCWs (149/197, 75.6%) were
recruited from TB contact investigations after limited
exposure to culture-confirmed TB source cases. As
there was no evidence of ongoing transmission among
those HCWs, all had been classified as medium TB
screening risk after the baseline evaluation and had been
referred to OSH screening for follow-up. One hundred
and forty-four HCWs had been exposed to a single
smear-negative TB source case with low contagiosity
[28], one HCW had been exposed to another smear-
negative source case, and four HCWs had had limited
contact ≤ 8 hours to a smear-positive source case.
All subjects were evaluated at baseline using a standar-
dized interview and questionnaire, a one-step Mantoux
TST (two tuberculin units, 0.1 ml purified protein derivate
[PPD] RT 23, Statens Serum Institute, Copenhagen,
Denmark), the IGRA QFT-GIT (Cellestis, Carnegie, Aus-
tralia), and chest x-ray if the baseline QFT-GIT results
were positive or showed a conversion at follow-up. The
follow-up included a second QFT-GIT only. The subse-
quent suggestion for a preventive chemotherapy according
to current national and international recommendations
[1,8], as well as the determination regarding the interval
between both IGRAs were the responsibility of the respec-
tive occupational physician. The latter mainly depended
on the underlying screening risk classification, and the fact
whether the respective HCW was screened according to
the “infection protection act”,o rt h e“biological agents
regulation” of the German OSH legislation, i. e. if the fol-
low-up QFT-GIT was performed rather short-term after
participation in a recent contact investigation (e. g. 3-6
months after the baseline evaluation), or if the HCW was
subject to (bi-)annual routine screening according to his
workplace risk (e. g. someone working in ID/TB care with-
out recent exposure).
Inclusion criteria were an age of 18 years and above,
engagement in health care during the study period, and
both valid baseline TST and QFT-GIT as well as follow-
up QFT-GIT results. Individuals who were recruited
from a setting with evidence of ongoing transmission or
who had been exposed to smear-positive TB > 8 hours
were excluded. The study cohort was longitudinally
observed regarding the progression to active TB for a
period of more than two years until February 7
th 2010
(32 months in the median). All HCWs were followed up
according to German OSH legislation. QFT-GIT-posi-
tive subjects were radiologically followed up as recom-
mended by national guidelines [8].
Diagnostic methods
The questionnaire, the evaluation of exposure, the appli-
cation of the TST, and the performance of the QFT-
GIT have been described previously [28]. The BCG
vaccination status was reassured by medical records
or the presence of vaccination scars. The baseline TST
and QFT-GIT were performed simultaneously. TST
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considered positive according to the respective clinical
situation, the TB screening risk classification, and
national and international guidelines [8,27]. The occupa-
tional physicians who read the TST were blinded to the
QFT-GIT results determined by the laboratory team
and vice versa. The QFT-GIT was performed according
to the manufacturer’s instructions that consider a result
positive if the IFN-g response of TB antigen minus Nil
was ≥ 0.35 IU/ml [29]. Conversion was defined as a
baseline IFN-g concentration < 0.35 IU/ml and a follow-
up IFN-g concentration ≥ 0.35 IU/ml. Reversion was
defined vice versa. All IGRAs were retested at the same
center as the baseline IGRA.
Statistical analysis
Data analysis was performed using SPSS, version 11.5
(SPSS Inc., Chicago, Illinois). Categorical data were com-
pared by Pearson’s chi-squared or Fisher’s exact test,
where appropriate. Normal distribution in continuous
variables was determined with the Kolmogorov-Smirnov
test and differences were subsequently determined either
with the paired student’s t-test, the Mann-Whitney-
U-test, or the Wilcoxon test. Spearman correlation coeffi-
cients and kappa values were calculated for both tests.
Independent predictors of persistent QFT-GIT positivity
were identified using logistic regression. All potential
predictors or confounders of interest were entered simul-
taneously and model building was performed backward
using the chance criteria for variable selection. Variables
considered to be clinically significant were retained
regardless of statistical significance [30]. Relations were
described as adjusted odds ratio (OR) and 95% confi-
dence interval (CI), with significance assessed by p-values
computed from Wald statistics. All p-values reported
were calculated two-tailed with statistical significance set
to p ≤ 0.05. The study protocol was approved by the
ethics committee of the Hamburg Medical Council and
the Ruhr-University Bochum. All study participants gave
their written and informed consent.
Results
Study population
One hundred and ninety-seven HCWs were enrolled in
the present study. Fifteen subjects (with negative QFT-
GIT results) were lost to follow-up or refused repeated
testing. Finally, 182 HCWs (92.4%) constituted the study
population (Figure 1). The demographic and clinical fea-
tures of the study population are shown in Table 1. The
median interval between both QFT-GIT was 18 weeks
(range 11-105 weeks). The mean age was 38 ± 10 years
(range 19-62) and the mean duration of employment in
health care was 14 ± 10 years (range 1-42). As these vari-
ables were highly correlated (r = 0.73, p < 0.0001), the
latter was not considered for further analysis. The major-
ity of subjects included in the final study population were
recruited from TB contact investigations (134/182,
73.6%). Of those, 129 HCWs (96.3%) had been exposed
to a single smear-negative source case. The median
cumulative exposure time among all subjects recruited
from contact investigations was 1.0 hour (range 3 min-
utes to 67 hours). Exposure > 40 hours occurred in four
individuals only, who had all been exposed to smear-
negative TB. However, exposure time had no significant
impact on the subsequent test results among this subpo-
pulation (see additional file 1: Influence of exposure to
TB source cases on subsequent test results, which also
provides a detailed description of the four HCWs that
had been exposed to smear-positive TB source cases).
Prior and baseline TST results
The prior and the recent TST results are shown in Table
1. The TST was administered at baseline only. One hun-
dred and twenty-nine subjects (70.9%) had been tested
with a prior TST, in the median 5 years ago (range 3
months to 38 years). In most instances, the prior TST
had been administered by the qualitative multi-puncture
method (115/129, 89.1%) and showed no significant
effect on the baseline TST and QFT-GIT results (see
additional file 2: Table S2 - Agreement and time interval
between prior and baseline TST and QFT-GIT results).
QFT-GIT results and agreement with recent TST results
The QFT-GIT results at baseline and at follow-up are
s h o w ni nT a b l e1a n dF i g u r e1 .T h et o t a lf r e q u e n c yo f
indeterminate QFT-GIT results was 1.4% (5 of all 364 per-
formed IGRAs). Overall, the agreement between the TST
(> 5 mm cut-off) and baseline QFT-GIT results was low
(raw 72.5%,  = 0.17, p = 0.012), and only slightly better
with follow-up QFT-GIT results (raw 75.3%,  = 0.23, p <
0.001). At best, a moderate agreement was observed
among non-BCG-vaccinated subjects between the TST
(≥ 10 mm cut-off) and the baseline QFT-GIT (raw 89.2%,
 = 0.50, p < 0.001). Subjects with positive baseline QFT-
GIT results had significantly higher baseline IFN-g levels
when they were concordantly TST-positive (≥ 10 mm cut-
off, median 4.33 vs. 1.26 IU/ml, p = 0.001).
Consistency between baseline and follow-up QFT-GIT
results
Overall, 170 of 182 subjects (93.4%) had consistent
QFT-GIT results. Figure 2 shows the distribution of
IFN-g responses for positive and negative QFT-GIT
results at baseline and at follow-up. There was a strong
overall agreement between both QFT-GIT results ( =
0.70, p < 0.0001). The agreement between both QFT-
GIT results stratified according to prior and recent TST
results is shown in Table 2.
Ringshausen et al. BMC Infectious Diseases 2010, 10:220
http://www.biomedcentral.com/1471-2334/10/220
Page 3 of 11Frequency of inconsistent QFT-GIT results
Inconsistent QFT-GIT results occurred in 12 of 182
HCWs (6.6%), and thus were comparatively rare even
when using a simplistic dichotomous negative-to-posi-
tive approach. The characteristics of individuals with
inconsistent QFT-GIT results are shown in Table 3.
Three of 162 subjects had conversions (1.9%), and six of
18 subjects had reversions (33.3%, Figure 1, Figure 2).
Another three subjects had inconsistent results includ-
ing indeterminate QFT-GIT results (a change from
negative to indeterminate and vice versa, Figure 1).
Notably, a significant proportion of conversions and
reversions occurred around the manufacturer’sp r e d e -
fined cut-off (Table 3).
Impact of age, TST induration and baseline IFN-g
concentration on follow-up QFT-GIT results
Subjects with persistently positive QFT-GIT results were
older (median age 52 vs. 38 years, p < 0.001), had larger
TST indurations (median 13 vs. 0 mm, p = 0.006), and
had higher IFN-g responses at baseline compared to
subjects with reversions at follow-up (median 3.22 vs.
0.59 IU/ml, p < 0.001, Figure 3).
Predictors of persistent QFT-GIT positivity
Multiple logistic regression analysis demonstrated that
the chance of persistent QFT-GIT positivity increased
with advancing age, a positive prior TST result, and a
recent TST result > 5 mm and ≥ 10 mm induration,
respectively. Furthermore, each additional 0.1 IU/ml
increase in the baseline IFN-g response raised the likeli-
hood of having persistently positive QFT-GIT results by
3% (OR 1.03, 95% CI, 1.01-1.04, Table 4).
Clinical outcome and follow-up
Active TB was ruled out by chest X-ray in all participants
with positive baseline QFT-GIT results and those with
conversions. None of the 182 study subjects developed
Figure 1 Study flow chart with baseline and follow-up QFT-GIT results. HCWs = health care workers; QFT-GIT = QuantiFERON®-TB Gold In-
Tube; TST = tuberculin skin test.
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two years (32 months in the median, range 25-50).
Discussion
To our knowledge, the present study is the first study,
which evaluated the use of an IGRA in the serial testing
of HCWs in a TB low-incidence country, and moreover,
systematically analyzed predictors of consistent IGRA
results. We observed a strong overall agreement between
baseline and follow-up QFT-GIT results that further
improved in subjects with positive prior and recent TST
results. However, reversions occurred in about one third
of initially QFT-GIT-positive study subjects. Persistent
QFT-GIT positivity was independently predicted by age,
prior and recent TST results, and the extent of baseline
IFN-g responses over a median interval of 18 weeks.
Comparison with previous literature in the field
We found a similarly low rate of positive QFT-GIT
results at baseline (9.9%) and follow-up (8.2%) compared
to recent TST results (28.6% with a threshold > 5 mm
and 24.2% with a threshold ≥ 10 mm). In accordance
with studies among HCWs in comparable epidemiologi-
cal settings, we observed a poor overall agreement
between IGRA and TST results due to BCG vaccination
in the majority of individuals [31-33]. Even with simplis-
tic negative-to-positive (and vice versa) definitions, and
moreover, considering indeterminate IGRA results we
found a comparatively low overall frequency of inconsis-
tent IGRA results of 6.6% (12/182). In line with previous
studies among HCWs, we observed more reversions (6/
18, 33.3%) than conversions (3/162, 1.9%). In a recent
study among 311 Japanese HCWs the IGRA conversion
rate was comparable to the one we determined (1.8%),
Table 1 Characteristics of the study population
Variables n %
Subjects, total 182 100
TB screening risk classification
Low risk 17 9.3
Medium risk 165 90.7
Reason for serial testing
(Bi-)Annual routine screening 48 26.4
Follow-up after recent contact investigation 134 73.6
Sex
Male 59 29.1
Female 123 70.9
Age categorized
18 to 39 years 104 57.1
40 to 49 years 50 27.5
≥ 50 years 28 15.4
Foreign country of birth* 40 22.0
Birth in high-burden country
# 8 4.4
BCG vaccination
Yes 95 52.2
No 75 41.2
Unknown 12 6.6
Health care professions
Nursing 56 30.8
Physician 28 15.4
Other 98 53.8
Affiliation with ID/TB Care 43 23.6
Family history of TB 14 7.7
Own history of TB 2 1.1
Prior TST 129 70.9
TST results
Positive prior TST result 54 41.9
Recent TST > 5 mm induration 52 28.6
Recent TST ≥ 10 mm induration 44 24.2
QFT-GIT results at baseline
Positive 18 9.9
Negative 162 89.0
Indeterminate 2 1.1
QFT-GIT results at follow-up
Positive 15 8.2
Negative 164 90.1
Indeterminate 3 1.7
*Mostly Turkey (n = 17) and Poland (n = 9).
#TB high-burden countries
(according to WHO): Belarus (n = 2), Bosnia and Herzegovina (n = 1),
Kazakhstan (n = 2), Morocco (n = 2), Philippines (n = 1). BCG = Bacillus
Calmette-Guérin; ID = Infectious Diseases. QFT-GIT = QuantiFERON®-TB Gold
In-Tube. TB = tuberculosis; TST = tuberculin skin test.
Figure 2 Distribution of IFN-g responses in the baseline and
the follow-up QFT-GIT. The responses of four subjects with
indeterminate QFT-GIT results are not shown. The vertical and the
horizontal dashed lines represent the QFT-GIT’s diagnostic cut-off of
0.35 IU/ml. IFN-g responses ≥ 10 IU/ml are shown as 10 IU/ml, IFN-g
responses < 0.00 IU/ml are shown as 0.00 IU/ml. IFN = interferon;
QFT-GIT = QuantiFERON®-TB Gold In-Tube.
Ringshausen et al. BMC Infectious Diseases 2010, 10:220
http://www.biomedcentral.com/1471-2334/10/220
Page 5 of 11Table 2 Consistency between baseline and follow-up QFT-GIT stratified by TST
Follow-up QFT-GIT
Baseline QFT-GIT Positive (n = 15)
n (%)
Negative (n = 163)
n (%)
Agreement
All subjects*
(n = 178)
Positive (n = 18) 12 (6.7) 6 (3.4) Raw = 94.9%
 = 0.70
#
Negative (n = 160) 3 (1.7) 157 (88.2)
Positive prior TST
(n = 54)
Positive (n = 9) 9 (16.7) 0 Raw = 100%
 = 1.0
#
Negative (n = 45) 0 45 (83.3)
Recent TST > 5 mm
(n = 51)
Positive (n = 10) 9 (17.6) 1 (2.0) Raw = 94.1%
 = 0.82
#
Negative (n = 41) 2 (3.9) 39 (76.5)
Recent TST ≥ 10 mm
(n = 44)
Positive (n = 10) 9 (20.5) 1 (2.3) Raw = 93.2%
 = 0.81
#
Negative (n = 34) 2 (4.5) 32 (72.7)
*Four individuals with indeterminate QFT-GIT results were excluded from this analysis.
#p < 0.0001, each. QFT-GIT = QuantiFERON®-TB Gold In-Tube. TST =
tuberculin skin test.
Table 3 Characteristics of the subjects with inconsistent QFT-GIT results (n = 12)
TST results IFN-g (IU/ml)
ID
No.
Age Sex Country
of birth
Family
history of TB
(year)
Profession (department/center)
-
exposure or risk classification
BCG
vaccination
Prior
TST*
Recent
TST
(mm)
Baseline Follow-
up
IGRA time
interval
(weeks)
Conversions
# (n = 3)
079 54 F Germany No Room cleaning (B) -
Contact tracing (SNCP, 90 min)
§
Yes No 10 0.06 0.46 17
151 39 F Germany 1967 Administration (Pulmonary/G) -
Routine screening (medium risk)
No No 0 0.01 0.46 52
177 50 F Germany 1990 Nursing (ER/G) -
Routine screening (medium risk)
Yes Neg.
(45)
10 0.26 4.33 54
Reversions
# (n = 6)
008 30 F Turkey No Room cleaning (B) -
Contact tracing (SNCP, 20 min)
§
Unknown No 0 22.66 0.01 17
015 38 M Germany No Nursing (Surgery/B) -
Contact tracing (SNCP, 44 h)
§
Yes Neg.
(52)
0 0.41 0.00 19
072 54 F Germany 1955 Nursing (Surgery/B) -
Contact tracing (SNCP, 4 h)
§
No Neg.
(5)
10 0.77 0.16 18
095 39 M Germany No Physical therapy (Rehabilitation/B)
- Contact tracing (SNCP, 4 h)
§
Yes Neg.
(57)
0 29.34 0.00 16
124 44 F Germany No Physical therapy (Rehabilitation/B)
- Contact tracing (SNCP, 3 h)
§
Yes Neg.
(86)
0 0.41 0.00 17
265 26 F Germany No Administration (ER/H) -
Contact tracing (SPCP, 8 h)
§
No No 0 0.40 0.00 22
Discordantly indeterminate (n = 3)
086 50 F Germany No Nursing (Surgery/B) -
Contact tracing (SNCP, 9 h)
§
No Pos.
(37)
0 0.00 0.00
† 17
173 20 F Germany No Nursing (Pulmonary/G) -
Routine screening (medium risk)
Yes No 7 0.01
† 0.01 51
187 26 F Germany No Nursing (Surgery/B) -
Contact tracing (SNCP, 67 h)
§
Yes Neg.
(60)
0 0.02 0.03
† 21
*The interval between the prior and the recent TST in months is indicated in parentheses.
#QFT-GIT conversions are defined as baseline IFN-g < 0.35 IU/ml and
follow-up IFN-g ≥ 0.35 IU/ml, QFT-GIT reversions are defined vice versa.
§The mean interval between the last exposure to the source case and the baseline
evaluation was 17 weeks in individuals initially included in contact investigations.
†Indeterminate QFT-GIT result due to insufficient IFN-g mitogen response. B =
Bochum; BCG = Bacillus Calmette-Guérin; ER = emergency room; F = female; G = Großhansdorf; H = Hamburg; IFN = interferon; M = male; QFT-GIT =
QuantiFERON®-TB Gold In-Tube; SNCP = smear-negative, culture-positive (tuberculosis source case); SPCP = smear-positive, culture-positive (tuberculosis source
case); TST = tuberculin skin test.
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Another study from Singapore, an intermediate-inci-
dence country, retested IGRA-negative junior physicians
only and described a conversion rate of 4.9% (9/182)
[21]. Pai and colleagues reported conversion and rever-
sion rates of 11.6% and 24%, respectively, among HCWs
in India, a high-incidence country [7].
We observed significant associations between the
extent of baseline IFN-g responses and the concordance
of TST and QFT-GIT positivity, as well as the extent of
TST induration and persistent QFT-GIT positivity.
Accordingly, logistic regression analysis confirmed a sig-
nificant relation between TST results, the extent of
baseline IFN-g responses and persistent QFT-GIT posi-
tivity. These findings are consistent with observations
from several previous studies. In a British study
following a TB outbreak, untreated contacts who
remained persistently IGRA-positive had had TST reac-
tions equivalent to Mantoux responses of 5-14 mm
induration, whereas those with reversions had been
TST-negative at baseline [13]. Two studies among
Indian household contacts and HCWs, respectively,
found that QFT-GIT reversions were significantly more
likely when the baseline TST was negative and when the
baseline IFN-g response was close to the diagnostic
threshold [7,12]. Likewise, a follow-up study among a U.
S. foreign-born population found significantly lower
baseline IFN-g levels in individuals with reversions com-
pared to those with persistently positive QFT-GIT
results (mean 0.56 vs. 4.99 IU/ml) [25].
Contradictory results have been reported [34], but
considering a recent systematic review, a previous TST
Figure 3 Comparison of the baseline level of IFN-g responses and consistency of QFT-GIT results. The short bar represents the median
level of IFN-g responses in subjects with positive baseline results (3.22 vs. 0.59 IU/ml, p < 0.001). The baseline IFN-g responses of the subjects
with conversions and consistently negative results are plotted for comparison. The responses of four subjects with indeterminate results are not
shown. The dashed line represents the diagnostic cut-off ≥ 0.35 IU/ml. IFN-g responses ≥ 10 IU/ml are shown as 10 IU/ml, IFN-g responses < 0.00
IU/ml are shown as 0.00 IU/ml. IFN = interferon; QFT-GIT = QuantiFERON®-TB Gold In-Tube.
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ESAT-6 and CFP-10 are also present in PPD [35]. How-
ever, the lower frequency of positive QFT-GIT results at
follow-up as well as the broad intervals between the
TST applications and the subsequent tests indicate that
boosting may not be a relevant phenomenon among our
study population.
Limitations
The present study is subject to limitations. Due to the
small sample size, we were unable to determine inde-
pendent risk factors for conversions and reversions. In
addition, an inevitable limitation is the fact that there is
no gold standard for the diagnosis of LTBI, and both
IGRAs and the TST indicate lasting immune responses
after exposure to MTB rather than the presence of
viable replicating mycobacteria [2].
Interpretation of findings
The fact that age and a positive prior TST were inde-
pendent predictors of persistent QFT-GIT positivity
may indicate the presence of long-standing MTB-speci-
fic immune responses, and thus, supports a rather
remote immunological contact with MTB among the
persistently QFT-GIT-positive individuals in our study
[31,36]. No secondary TB cases were detected within
the observational period. Recently, first evidence for the
moderate predictive ability of a single positive IGRA
result, or correspondingly, a documented IGRA conver-
sion after recent extensive exposure to smear-positive
Table 4 Predictors of persistent QFT-GIT positivity
Positive Baseline and follow-up QFT-GIT
Variables Adjusted OR* (95% CI) p-value
Age categorized
# 5.0 (3.9-13.5) 0.001
Sex
Female 1 -
Male 1.2 (0.2-6.3) 0.80
Birth in high-burden country
No 1-
Yes 0.2 (0.0-3.6) 0.29
BCG status 1 -
Vaccinated 0.3 (0.1-1.5) 0.15
Unknown 0.6 (0.0-9.8) 0.70
Profession
Other 1 -
Nursing 0.6 (0.1-3.4) 0.57
Physician 3.2 (0.5-22.7) 0.24
Affiliation with ID/TB Care
No 1-
Yes 0.8 (0.1-7.8) 0.85
Family history of TB
No 1-
Yes 1.1 (0.1-8.7) 0.96
QFT-GIT test interval per day 1.0 (0.99-1.01) 0.49
Exposure per hour
§ 0.7 (0.45-1.13) 0.15
Prior TST
Negative 1 -
Positive 14.2 (1.4-143.2) 0.024
Recent TST
Negative 1 -
> 5 mm induration 12.1 (2.4-59.8) 0.002
≥ 10 mm induration 15.5 (3.1-81.3) 0.001
Baseline IFN-g increase per 0.1 IU/ml 1.03 (1.01-1.04) 0.0006
*Variables included in final model building were age, birth in high-burden country, BCG status, recent TST result > 5 mm or ≥ 10 mm induration, and baseline
IFN-g increase per 0.1 IU/ml.
#Compare Table 1.
§Exposure per hour in those 134 study subjects that were recruited from contact investigations. BCG = Bacillus
Calmette-Guérin; CI = confidence interval; ID = Infectious Diseases; IFN = interferon; OR = odds ratio; QFT-GIT = QuantiFERON®-TB Gold In-Tube; TB =
tuberculosis; TST = tuberculin skin test.
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available [37-41]. In these studies the rate of QFT-GIT-
positive subjects progressing to active TB ranged from
2.8-17.2%. In contrast, up to date there is virtually no
data regarding the interpretation and clinical relevance
of persistently positive IFN-g responses in serial testing
or in the absence of recent extensive exposure [42,43].
However, our findings support the hypothesis that the
risk of progression to active TB is likely to be low
among those HCWs with persistently positive QFT-GIT
results in the absence of recent extensive TB exposure.
Considering the dynamic characteristics of IFN-g
responses over time, which increase the chance of IGRA
conversions and reversions, a simplistic dichotomous
negative-to-positive definition may not be appropriate
[44]. Although only a limited number of recent studies
focused on the within-subject variability (reproducibility)
of IGRA results [18-20,35], a variety of different borderline
or uncertainty zones around the manufacturers’ prede-
fined cut-points as well as definitions of “true” conversions
and reversions have been suggested in order to improve
the interpretation of IGRA results in serial testing
[7,9,12,18-20,25]. When we arbitrarily applied a borderline
zone of 0.20-0.70 IU/ml [20], and an increase from < 0.35
to ≥ 0.70 IU/ml as a definition of a “true” conversion
[7,12], only one of three conversions (1/162, 0.6%) and
half of six reversions (3/18, 16.7%) may be considered as
“true” conversion and reversion, respectively (Table 3).
We observed three individuals with sharp positive-to-
negative IFN-g declines (No. 8, 72 and 95, compare Table
3), which may rather represent “true” reversions, e. g. due
to clearing of acute infection or transition into dormancy
than nonspecific variation [10,42,44].
Clinical relevance of findings
Nonspecific variation, conversions, and reversions occur
with IGRA serial testing, just as they do with the TST
[7,35]. Our data suggests the usefulness of a borderline
zone including unspecific variation around the manufac-
turer’s predefined cut-off in order to avoid misinterpre-
tations of IGRA results. Values within this zone should
be interpreted with caution, and relevant clinical infor-
mation should always be considered. One should bear in
mind that neither LTBI nor active TB can be completely
excluded by a single or even repeated negative IGRA
results [10,45,46]. On the contrary, the possibility of a
false positive IGRA result should be considered in TST-
negative/IGRA-positive subjects, especially if it is close
to the cut-off. Hence, laboratories should provide abso-
lute IFN-g values, and expert opinion should be sought
for the interpretation of IGRA results in serial testing, if
necessary.
We found that older HCWs, those with concordantly
positive TST and QFT-GIT results, and those with high
baseline IFN-g responses had a significant chance to
remain persistently QFT-GIT-positive over a median
interval of 18 weeks. Consequently, repeated QFT-GIT
testing may not be the diagnostic tool of choice in order
to follow-up these subjects according to their workplace
risk, and hence, a chest X-ray should be favored instead.
However, these findings need further confirmation.
So far, it appears that IGRA responses over time sig-
nificantly depend on the epidemiologic setting, in which
these tests are applied, and different thresholds may be
appropriate for different populations. However, uniform
definitions of QFT-GIT conversions, reversions, and
borderline zones among different populations remain to
be defined yet. Thus, further research on the within-
subject variability and the predictive value of (repeatedly
positive) IGRA responses (and their predictors) in serial
testing is warranted [10,35,43,44].
Conclusions
The QFT-GIT’s utility for the application in serial test-
ing was limited by a substantial proportion of reversions.
This shortcoming could be overcome by the implemen-
t a t i o no fab o r d e r l i n ez o n ef o rt h ei n t e r p r e t a t i o no f
QFT-GIT results. However, further studies are needed
to clearly define the within-subject variability of the
QFT-GIT and to confirm that increasing age, concor-
dantly positive TST results, and the extend of baseline
IFN-g responses may predict the persistence of QFT-
GIT positivity over time in serially tested HCWs with
only a low or medium TB screening risk in a TB low-
incidence setting.
Additional material
Additional file 1: Influence of exposure to TB source cases on
subsequent test results. The data demonstrates that there were no
significant differences between the median cumulative exposure times
with regard to subsequent test results among the subpopulation
recruited from contact investigations, and furthermore, provides a
detailed description of the four HCWs that had been exposed to smear-
positive TB source cases.
Additional file 2: Table S2 - Agreement and time interval between
prior and baseline TST and QFT-GIT results. This table demonstrates
that the prior TST had no significant effect on baseline TST and QFT-GIT
results.
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